ONCSM.E — Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapHigh Flyer

Market Cap
TRY3.81bn
Enterprise Value
TRY3.83bn
Revenue
TRY374.49m

Annual income statement for Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS, fiscal year end - December 31st, TRY millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	R2022 December 31st	R2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	101	128	293	347	374
Cost of Revenue
Gross Profit	38.3	88.3	101	51.7	139
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	73.8	55.9	258	439	368
Operating Profit	27.5	72.1	34.8	-92	6.16
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	23.9	80.4	-2.5	-136	-50.8
Provision for Income Taxes
Net Income After Taxes	18.8	71.7	-20.8	-115	-59.2
Minority Interest
Net Income Before Extraordinary Items
Net Income	18.7	71.7	-20.8	-115	-59.2
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	18.7	71.7	-20.8	-115	-59.2
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.766	2.62	-0.794	-4.87	-2.48
Dividends per Share